Age | 61.2 ± 8.6 |
---|---|
M/F | 16/3 (84.2/15.8) |
BMI | 27.6 ± 4.6 |
Hypertension | 7 (36.8) |
TIA/CVA | 1 (5.2) |
Preoperative catheter ablation | Â |
AF | 4 (21.1) |
Flutter | 5 (26.3) |
Type of preoperative AF | Â |
Paroxysmal | 5 (26.3) |
Persistent | 4 (21.1) |
Long-standing persistent | 10 (52.6) |
Prevalence of AF (68% CI) | Â |
Paroxysmal | 20.0 (16.8–23.3) |
Persistent | 34.7 (31.2–38.9) |
Long-standing persistent | 63.6 (59.9–67.1) |
EHRA Score | 4 [3–4] |
Duration of preoperative AF (yrs.) | 5 [3–8.5] |
Antyarrhythmic Drugs | Â |
Amiodaron | 2 (10.5) |
Dysopiramide | 1 (5.3) |
Flecainide | 6 (31.5) |
Propaphenon | 1 (5.3) |
Sotalol | 5 (26.3) |
Electrical cardioversion | 15 (78.9) |
Previous Catheter Ablation | Â |
For AF | 6 (31.5) |
For Atrial Flutter | 5 (26.3) |
Preoperative Pacemaker | 2 (10.5) |
Anticoagulant status | Â |
Sodium Warfarin | 16 (84.2) |
Aspirin | 5 (26.3) |
LAVI (mL/m2) | 47 ± 11 |
LAMAX (mL/m2) | 49 ± 20 |
LAMIN (mL/m2) | 30 ± 15 |
LAEF (%) | 38 ± 12 |
LA A-P (cm) | 5.0 ± 0.5 |
LA S-I (cm) | 6.4 ± 0.5 |